DYN vs. ORKA

Last updated Jun 4, 2026

DYN (Dyne Therapeutics, Inc.) and ORKA (Oruka Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, DYN returned -0.17%/yr vs 19.94%/yr for ORKA. At a 0.27 correlation, their price movements are largely independent.

Performance

DYN vs. ORKA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dyne Therapeutics, Inc. (DYN) and Oruka Therapeutics, Inc (ORKA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DYN achieves a -8.03% return, which is significantly lower than ORKA's 88.72% return.

DYN

• 1D: 4.35%
• 1M: 1.58%
• YTD: -8.03%
• 6M: -10.45%
• 1Y: 35.57%
• 3Y*: 10.23%
• 5Y*: -0.17%
• 10Y*: —

ORKA

• 1D: 3.57%
• 1M: -13.93%
• YTD: 88.72%
• 6M: 93.24%
• 1Y: 379.06%
• 3Y*: 61.35%
• 5Y*: 19.94%
• 10Y*: -17.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DYN vs. ORKA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
DYN Dyne Therapeutics, Inc.	-8.03%	-16.98%	77.14%	14.75%	-2.52%	-43.38%	-12.13%
ORKA Oruka Therapeutics, Inc	88.72%	56.32%	76.73%	-28.27%	10.23%	-46.38%	-20.91%

Correlation

The correlation between DYN and ORKA is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.43
Correlation (3Y) Calculated over the trailing 3-year period	0.34
Correlation (5Y) Calculated over the trailing 5-year period	0.31
Correlation (All Time) Calculated using the full available price history since Sep 18, 2020	0.27

The correlation between DYN and ORKA shifts across timeframes, from 0.27 (all time) to 0.43 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap DYN : $2.97B ORKA : $3.16B
EPS DYN : -$3.29 ORKA : -$2.37
PB Ratio DYN : 3.43 ORKA : 6.52
Total Revenue (TTM) DYN : $0.00 ORKA : $0.00
Gross Profit (TTM) DYN : -$521.00K ORKA : -$71.00K
EBITDA (TTM) DYN : -$441.38M ORKA : -$125.61M

Return for Risk

DYN vs. ORKA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DYN

DYN Risk / Return Rank: 58
DYN Sharpe Ratio Rank: 56
DYN Sortino Ratio Rank: 60
DYN Omega Ratio Rank: 59
DYN Calmar Ratio Rank: 58
DYN Martin Ratio Rank: 56

ORKA

ORKA Risk / Return Rank: 97
ORKA Sharpe Ratio Rank: 98
ORKA Sortino Ratio Rank: 97
ORKA Omega Ratio Rank: 94
ORKA Calmar Ratio Rank: 98
ORKA Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DYN vs. ORKA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dyne Therapeutics, Inc. (DYN) and Oruka Therapeutics, Inc (ORKA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DYN	ORKA	Difference
Sharpe ratio: Return per unit of total volatility	0.43	5.10	-4.67
Sortino ratio: Return per unit of downside risk	1.26	4.64	-3.38
Omega ratio: Gain probability vs. loss probability	1.16	1.55	-0.39
Calmar ratio: Return relative to maximum drawdown	0.80	13.65	-12.85
Martin ratio: Return relative to average drawdown	1.48	45.14	-43.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DYN vs. ORKA - Sharpe Ratio Comparison

The current DYN Sharpe Ratio is 0.43, which is lower than the ORKA Sharpe Ratio of 5.10. The chart below compares the historical Sharpe Ratios of DYN and ORKA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	DYN	ORKA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.43	5.10	-4.67
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.00	0.28	-0.28
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.11	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	-0.23	+0.17

Drawdowns

DYN vs. ORKA - Drawdown Comparison

The maximum DYN drawdown since its inception was -85.52%, smaller than the maximum ORKA drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for DYN and ORKA.

Drawdown Indicators

	DYN	ORKA	Difference
Max Drawdown Largest peak-to-trough decline	-85.52%	-100.00%	+14.48%
Max Drawdown (1Y) Largest decline over 1 year	-44.65%	-27.99%	-16.66%
Max Drawdown (3Y) Largest decline over 3 years	-85.52%	-77.76%	-7.76%
Max Drawdown (5Y) Largest decline over 5 years	-85.52%	-77.76%	-7.76%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.38%	—
Current Drawdown Current decline from peak	-61.76%	-100.00%	+38.24%
Average Drawdown Average peak-to-trough decline	-50.71%	-93.87%	+43.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.15%	8.45%	+15.70%

Volatility

DYN vs. ORKA - Volatility Comparison

Dyne Therapeutics, Inc. (DYN) has a higher volatility of 21.21% compared to Oruka Therapeutics, Inc (ORKA) at 16.19%. This indicates that DYN's price experiences larger fluctuations and is considered to be riskier than ORKA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DYN	ORKA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.21%	16.19%	+5.02%
Volatility (6M) Calculated over the trailing 6-month period	49.92%	50.17%	-0.25%
Volatility (1Y) Calculated over the trailing 1-year period	82.98%	74.88%	+8.10%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	79.64%	72.23%	+7.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.67%	152.46%	-73.79%

Dividends

DYN vs. ORKA - Dividend Comparison

Neither DYN nor ORKA has paid dividends to shareholders.

Position	TTM	2025	2024
DYN Dyne Therapeutics, Inc.	0.00%	0.00%	0.00%
ORKA Oruka Therapeutics, Inc	0.00%	0.00%	99.82%

Financials

Frequently Asked Questions

Can I hold both DYN and ORKA in my portfolio?

DYN and ORKA have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DYN or ORKA?

DYN has higher volatility (21.21%) compared to ORKA (16.19%). In terms of maximum drawdown, DYN dropped -85.52% vs ORKA's -100.00%.

Which has better risk-adjusted returns?

ORKA currently has the higher Sharpe Ratio (5.10 vs 0.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.